[1] Ahmad Z, Tyagi S, Minkowski A,et al. Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis. Am J Respir Critical Care Med, 2013,188(1):97-102.
[2] Takiff H, Guerrero E. Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob Agents Chemother, 2011, 55(12):5421-5429
[3] Ahuja SD, Ashkin D, Avendano M, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9153 patients. PLoS Med,2012,9(8):e1001300.
[4] 中国防痨协会.耐药结核病化学治疗指南（2015）.中国防痨协杂志, 2015,37(5):421-469.
[5] World Health Organization.WHO treatment guidelines for drug-resistant tuberculosis 2016 .Geneva:World Health Organization,2016.
[6]马屿，朱莉贞，潘毓萱，等. 结核病.北京：人民卫生出版社,2006:521-523.
[7].唐神结.氟喹诺酮类药物在耐多药结核病中应用的再评价.中华结核和呼吸杂志, 2014,37(10):727-728.
[8].Rustomjee R,Lienhardt C,Kanyok T,et al.A phase 11 study of the sterilizing activities of ofloxacin,gatifloxacin and
moxifloxacin in pulmonary tuberculosis.Int J Tuberc Lung Dis ,2008,12(2):128-138.
[9]..Chemades R,Rodrfguez JC,Carcfa-Pachon E,et al.Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an vitro experimental model.J Antimicrob Chemother,2011,66:2281-2283.
[10]..唐神结,李亮,高文,等.中国结核病年签(2015).北京:人民卫生出版社,2016:93-96.
[11]Velayutham BV,Allaudeen IS,Sivaramakrishnan GN,et al.Sputum culture conversion with moxifloxacin-containing regimens
inthe treatment of patients with newly diagnosed sputum-positive pulmonarytuberculosis in South India.Clin Infect Dis,2014,
59(10):e142-149.
[12]Chen Z, liang JQ, Wang JH, et al. Moxifloxacin plus standard frist-line therapy in the treatment of pulmonary tubercuosis:a meta-analysis.Tuberculosis (Edinb), 2015,95(4):490-496.
[13]Ziganshina LE,Titarenko AF,Davies GR. Fluoroquinolones for treating tuberculosis(presumed drug-
sensitive).Cochrane Database Syst Rev,2013,(6):CD004795.
[14] Jawahar MS,Banurekha VV,Paramasian CN,et al.Randomized clinical trial of thrice-weekly 4-month moxifloxacin or gatifloxacin containing regiments in the treatmeat of new sputum postive pulmonary tuberculosis patients.PLoS One,2013,8(7):e67030.
[15] Gillespie SH,Crook AM,MeHugh TD,et al.Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.N Engl
J Med,2014, 371(17):1577-1587.
[16] Jindani A,Harrison TS,Nunn AJ,et al.High-dose rifapentine with moxifloxacin for pulmonary tuberculosiss.N Engl J
Med,2014,371(17):1599-1608.
[17]Merle CS,Fielding K,Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med,2014,371(17):1588-1598.
[18]范琳娟.左氧氟沙星联合治疗复治菌阳肺结核的疗效分析. 医药前沿,2015，5（10）：76-77.
[19]刘宇红，杜建，高微微，等.含链霉素或左氧氟沙星方案治疗复治肺结核患者的近期疗效及安全性.中国防痨杂志，
2015，37（5）：487-493.
[20] Lee H, Jeong BH,Park HY,et al.Treatment outcomes with fluoroquinolone-containing reginments for isoniazid-resistant
pulmonary tuberculosis. Antimicrob Agents Chemother,2015,60（1）：471-477.
[21]Chien JY,Chen YT,Wu SG,et al.Treatment outcome of patients with isoniazid mono-resistant tuberculosiss.Clin Microbiol
Infect,2015,21(1):59-68.
[22]李琦，姜晓颖，梁建琴，等.含左氧氟沙星或莫西沙星方案治疗耐多药肺结核的疗效分析.中国防痨杂志，2016，
38(6)：436-442.
[23] Jiang RH, Xu HB, Li L. Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-
resistant tuberculosis:a retrospective study. Int J Antimicrob Agents,2013,42(1):36-41.
[24] Koh WJ,Lee SH,Kang YA ,et al.Comparison of levofioxacin versus moxifloxacin for multidrug-resistant tuberculosis .Am J
Respir Crit Care Med, 2013 ,188(7):858-864.
[25]范琳, 唐神结.莫西沙星治疗结核病值得注意的问题.中国实用内科杂志，2015，35（8）：668-670.
[26] Jo KW, Lee SD, Kim WS, et al. Treatment outcomes and moxifloxacin susceptibility in ofloxacin-resistant multidrug-
resistant tuberculosis. Int J Tuberc Lung Dis, 2014, 18(1): 39-43.
[27] World Health Organization. Compannion handbook to the WHO guidelines for the programmatic management of drug-
resistant tuberculosis. Geneva:World Health Organization,2014.
[28]王前, 宋媛媛, 逄宇, 等.耐氧氟沙星结核分枝杆菌对五种氟喹诺酮类药物交叉耐药性的研究.中国防痨杂志, 2014,36
（6）：453-457..
[29]World Health Organization.Cuideline for surveillance of drug resistance in tuberculosis［EB/OL］.Geneva:World Health
Organization,2014(2014-03-20)
[2017-02-12].http://www.who.int/tb/pulications/2009/surveillance-guidelines/en/.
[30]卢峰岳, 俞日霞, 胡族琼, 等.结核分枝杆菌DNA促旋酶基因突变与耐氟喹诺酮类药物的相关性研究.中国防痨杂志,
2014, 36（6）:429-433.
[31]Kambli P, Ajbani K, Sadani M, et al. Correlating Minimum Inhibitory Concentrations of ofloxacin and moxifloxacin with gyrA mutions the genotype MTBDRsl assay. Tuberculosis (Edinb), 2015,95(2):137-141
[32]Willy M,Sikes RD,Malik S,et al.Correlation between GyrA substitutions and ofloxacin, levofloxacin,and moxifloxacin
cross-resistance in Mycobacterium tuberculosis.Antimicrob Agents Chemother,2015,59(9):5427-5434.
[33] Rigouts L, Coeck N, Gumusboga M,et al.Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.J
Antimicob Chemother ,2016,71(2)：314-323.
[34]Devasia R, Blackman A, Eden S, et al. High proportion of fluoroquinolone-resistant Mycobacterium tuberculosis isolates
with novel gyrase polymorphisms and a gyrA region associated with fluoroquinolone susceptibility.J Clin Microbiol, 2012 ,
50(4):1390-1396. |
京公安网备11010202008787号
ip访问总数: ip当日访问总数: 当前在线人数:
本作品遵循Creative Commons Attribution 3.0 License授权许可
